Clinical Trial Update: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of FOLFOX-A for metastatic or unresectable gastroesophageal junction adenocarcinoma and gastric cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastro-esophageal Junction Adenocarcinoma

Drugs mentioned

• FOLFOX-A

Snippet

Sponsor: Al B. Benson, III, MD | Conditions: Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-06